乳腺癌YKL-40表达与预后关系的研究

Correlation of YKL-40 protein expression with prognosis of patients with breast cancer

目的:探讨YKL-40表达水平与乳腺癌预后相关因素的关系。方法:采用免疫组织化学SP法检测60例乳腺癌患者YKL-40表达,比较YKL-40表达与乳腺癌患者年龄、肿瘤直径、淋巴结转移、病理类型及TNM分期间的关系。结果:乳腺癌患者中YKL-40表达水平明显高于对照组(75%vs 20%,P<0.05)。肿瘤直径>2 cm患者YKL-40水平明显高于直径≤2cm组患者(P<0.05)。随着肿瘤TNM分期进展,血清YKL-40表达水平逐渐升高(P<0.05)。YKL-40在非浸润性和浸润性导管癌中表达率皆明显高于浸润性小叶癌(P<0.05)。YKL-40表达阳性患者生存时间短于阴性患者【(36±4.9)月vs(49±7.5)月,P<0.05】,本组平均随访(35.4±2.39)月,YKL-40表达阳性患者病死率为22.2%(10/45),表达阴性患者病死率为13.3%(2/15)。结论:YKL-40表达与乳腺癌预后相关,可望成为乳腺癌新的肿瘤标志物及治疗靶点。

Objection： To investigate the value of YKL-40 protein expression of tissue sam- ples in estimating the prognosis of breast cancer. Methods： The YKL-40 protein expression in tumor tissue was measured by immunohistochemistry in 60 patients with breast cancer. The dif- ferences of YKL-40 protein expression was compared in the parameters of age, tumor diameter, the amount of transferred lymph nodes, pathological type and TNM stage. Results： The YKL-40 protein expression in patients with breast cancer was higher than that in healthy female controls （75% vs 20%, P〈O.05）. YKL-40 protein expression were also higher in patients with tumour size 〉2 cm and ductal carcinomas than ≤2 cm and Iobular carcinomas,respectively （P〈O.05）. The YKL-40 protein expression increased with the advancement in TNM stage. The overall survival was 36 ± 4.9 months in YKL-40 positive patients versus 49 ± 7.5 months in YKL-40 negative pa- tients （P〈0.05）. The mean follow-up time was 35.4± 2.39 months.The death rate was seen in 22.2% and 13.3% patients in YKL-40 positive and YKL-40 negative patients, respectively. Conclusions： The YKL-40 protein expression in tumor tissue was correlative with progonosis of pa- tients with breast cancer, and may be a promosing tumor marker and target for molecular targeted therapy.